CN1674931A - T细胞受体cdr3序列和检测方法 - Google Patents

T细胞受体cdr3序列和检测方法 Download PDF

Info

Publication number
CN1674931A
CN1674931A CNA038186314A CN03818631A CN1674931A CN 1674931 A CN1674931 A CN 1674931A CN A038186314 A CNA038186314 A CN A038186314A CN 03818631 A CN03818631 A CN 03818631A CN 1674931 A CN1674931 A CN 1674931A
Authority
CN
China
Prior art keywords
sequence
seq
cells
nucleotides
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038186314A
Other languages
English (en)
Chinese (zh)
Inventor
臧敬五
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Opexa Pharmaceuticals Inc
Original Assignee
Baylor College of Medicine
Opexa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Opexa Pharmaceuticals Inc filed Critical Baylor College of Medicine
Publication of CN1674931A publication Critical patent/CN1674931A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
CNA038186314A 2002-06-05 2003-06-05 T细胞受体cdr3序列和检测方法 Pending CN1674931A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38628702P 2002-06-05 2002-06-05
US60/386,287 2002-06-05

Publications (1)

Publication Number Publication Date
CN1674931A true CN1674931A (zh) 2005-09-28

Family

ID=29736145

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038186314A Pending CN1674931A (zh) 2002-06-05 2003-06-05 T细胞受体cdr3序列和检测方法

Country Status (16)

Country Link
EP (1) EP1530483B1 (enExample)
JP (3) JP2005528910A (enExample)
CN (1) CN1674931A (enExample)
AT (1) ATE453727T1 (enExample)
AU (1) AU2003237437B2 (enExample)
BR (1) BR0311578A (enExample)
CA (1) CA2485874A1 (enExample)
DE (1) DE60330780D1 (enExample)
IL (2) IL165194A (enExample)
MX (1) MXPA04011646A (enExample)
NO (1) NO20044945L (enExample)
NZ (1) NZ537403A (enExample)
PL (1) PL213315B1 (enExample)
RU (1) RU2004139045A (enExample)
WO (1) WO2003104407A2 (enExample)
ZA (1) ZA200409792B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108070644A (zh) * 2016-11-08 2018-05-25 国家卫生计生委科学技术研究所 一种妊娠高血压的诊断系统
CN110546269A (zh) * 2017-03-15 2019-12-06 学校法人兵库医科大学 癌症免疫疗法的新型生物标志物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102488652B (zh) 2006-03-16 2014-06-18 特瑞斯制药股份有限公司 含有药物-离子交换树脂复合物的经修饰释放的制剂
BR112015003120B1 (pt) 2012-08-15 2022-08-09 Tris Pharma , Inc Tablete mastigável de liberação estendida de metilfenidato e seu uso
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
CA2362099C (en) * 1999-02-23 2014-05-13 Baylor College Of Medicine T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108070644A (zh) * 2016-11-08 2018-05-25 国家卫生计生委科学技术研究所 一种妊娠高血压的诊断系统
CN108070644B (zh) * 2016-11-08 2021-06-29 国家卫生计生委科学技术研究所 一种妊娠高血压的诊断系统
CN110546269A (zh) * 2017-03-15 2019-12-06 学校法人兵库医科大学 癌症免疫疗法的新型生物标志物
US11858994B2 (en) 2017-03-15 2024-01-02 Repertoire Genesis Incorporation Biomarkers for cancer immunotherapy

Also Published As

Publication number Publication date
BR0311578A (pt) 2007-04-27
AU2003237437A1 (en) 2003-12-22
ZA200409792B (en) 2006-07-26
NO20044945L (no) 2004-12-28
IL165194A0 (en) 2005-12-18
MXPA04011646A (es) 2005-03-07
JP2010207226A (ja) 2010-09-24
IL206650A0 (en) 2011-07-31
IL206650A (en) 2016-10-31
JP2005528910A (ja) 2005-09-29
EP1530483B1 (en) 2009-12-30
PL213315B1 (pl) 2013-02-28
AU2003237437B2 (en) 2010-11-25
IL165194A (en) 2010-11-30
EP1530483A4 (en) 2006-05-17
RU2004139045A (ru) 2005-09-10
DE60330780D1 (de) 2010-02-11
WO2003104407A3 (en) 2005-03-24
PL374723A1 (en) 2005-10-31
NZ537403A (en) 2009-10-30
EP1530483A2 (en) 2005-05-18
JP2013126420A (ja) 2013-06-27
WO2003104407A2 (en) 2003-12-18
CA2485874A1 (en) 2003-12-18
ATE453727T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
RU2138512C1 (ru) Вакцина для профилактики или лечения опосредованной т-клетками патологии или нерегулируемой репликации клонами т-клеток, способ выделения вакцины, способ диагностирования или прогнозирования восприимчивости к ревматоидному артриту или рассеянному склерозу, способ профилактики или лечения ревматоидного артрита или рассеянного склероза и содержащий последовательность sgdqggne пептид, являющийся агентом для обнаружения, профилактики или лечения рассеянного склероза
US20070238099A1 (en) Antigen Receptor Variable Region Typing
CA1339098C (en) Characterization and detection of sequences associated with autoimmune diseases
JP2001097886A (ja) 特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
NZ332715A (en) T-cell antigen receptor V region protein production by transforming a competent bacterial host cell
JP2007308502A (ja) Ｔ細胞レセプターＶβ−Ｄβ−Ｊβ配列
JP2013126420A (ja) Ｔ細胞レセプターｃｄｒ３配列および検出のための方法
AU660606B2 (en) Diagnosis and treatment of diseases
AU695801B2 (en) Interaction of T-cell receptors and antigen in autoimmune disease
CN1468123A (zh) 用于改变b细胞介导病理的方法和组合物
Fischer et al. Limited heterogeneity of rearranged T cell receptor Vα and Vβ transcripts in synovial fluid T cells in early stages of rheumatoid arthritis
EP0527199A1 (en) VARIABLE TRANSCRIPTS OF T LYMPHOCYTE RECEPTORS USED AS DISEASE MARKERS.
CA2297491A1 (en) Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens
WO2004060145A2 (en) Isolation and identification of cross-reactive t cells
US7744893B2 (en) T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
JP2004506743A (ja) Ｔ細胞レセプターＶβ−Ｄβ−Ｊβ配列およびその検出方法
CN1663603A (zh) 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
KR20050016491A (ko) 티세포 수용체 씨디알3 서열 및 검출방법
CN1465704A (zh) 抑癌基因pinx1及其应用
JP2006129832A (ja) ＣａｔｈｅｐｓｉｎＨタンパク質由来のＣＤ８＋細胞傷害性Ｔリンパ球ｍＨＡエピトープペプチド及びその用途
CN1665926A (zh) 同源补体介导下裂解活化淋巴细胞的人IgM抗体
JP2007319069A (ja) ＬＯＣ２８４２９３バリアント遺伝子並びに該遺伝子がコードするＣＤ８＋細胞傷害性Ｔリンパ球ｍＨＡエピトープペプチド及びその用途
CN1393452A (zh) 记忆清除蛋白及其应用
CN1661072A (zh) 精氨酸升压素受体1a基因与原发性高血压的相关性

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication